These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 27619514

  • 21. Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7.
    Nonn M, Schinz M, Zumbach K, Pawlita M, Schneider A, Dürst M, Kaufmann AM.
    J Cancer Res Clin Oncol; 2003 Sep; 129(9):511-20. PubMed ID: 12905010
    [Abstract] [Full Text] [Related]

  • 22. HPV16 E6 29-38-specific T cells kill cervical carcinoma cells despite partial evasion of T-cell effector function.
    Thomas KJ, Smith KL, Youde SJ, Evans M, Fiander AN, Borysiewicz LK, Man S.
    Int J Cancer; 2008 Jun 15; 122(12):2791-9. PubMed ID: 18366058
    [Abstract] [Full Text] [Related]

  • 23. Profile of regulatory T cells and interferon γ secretion in the tumor-draining lymph node from mouse Hepa1-6 cells.
    Wang LK, Kuang M, Hua YP, He Q, Chen B, Wang Y, Peng BG.
    J Surg Res; 2013 Aug 15; 183(2):900-6. PubMed ID: 23481561
    [Abstract] [Full Text] [Related]

  • 24. Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy.
    Li Q, Carr A, Ito F, Teitz-Tennenbaum S, Chang AE.
    Cancer Res; 2003 May 15; 63(10):2546-52. PubMed ID: 12750278
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells.
    Ohno K, Yoshizawa H, Tsukada H, Takeda T, Yamaguchi Y, Ichikawa K, Maruyama Y, Suzuki Y, Suzuki E, Arakawa M.
    J Immunol; 1996 May 15; 156(10):3875-81. PubMed ID: 8621926
    [Abstract] [Full Text] [Related]

  • 27. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.
    Chang AE, Yoshizawa H, Sakai K, Cameron MJ, Sondak VK, Shu S.
    Cancer Res; 1993 Mar 01; 53(5):1043-50. PubMed ID: 8439951
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Neoadjuvant therapy changes the lymphocyte composition of tumor-draining lymph nodes in cervical carcinoma.
    Fattorossi A, Battaglia A, Ferrandina G, Coronetta F, Legge F, Salutari V, Scambia G.
    Cancer; 2004 Apr 01; 100(7):1418-28. PubMed ID: 15042676
    [Abstract] [Full Text] [Related]

  • 30. Identification of human papillomavirus 16-E6 protein-derived peptides with the potential to generate cytotoxic T-lymphocytes toward human leukocyte antigen-A24+ cervical cancer.
    Hara M, Matsueda S, Tamura M, Takedatsu H, Tanaka M, Kawano K, Mochizuki K, Kamura T, Itoh K, Harada M.
    Int J Oncol; 2005 Nov 01; 27(5):1371-9. PubMed ID: 16211234
    [Abstract] [Full Text] [Related]

  • 31. Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens.
    Youde SJ, Dunbar PR, Evans EM, Fiander AN, Borysiewicz LK, Cerundolo V, Man S.
    Cancer Res; 2000 Jan 15; 60(2):365-71. PubMed ID: 10667589
    [Abstract] [Full Text] [Related]

  • 32. Circulating human papillomavirus type 16 specific T-cells are associated with HLA Class I expression on tumor cells, but not related to the amount of viral oncogene transcripts.
    de Boer MA, Jordanova ES, van Poelgeest MI, van den Akker BE, van der Burg SH, Kenter GG, Fleuren GJ.
    Int J Cancer; 2007 Dec 15; 121(12):2711-5. PubMed ID: 17724722
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Synergistic effects of IL-12 and IL-18 in skewing tumor-reactive T-cell responses towards a type 1 pattern.
    Li Q, Carr AL, Donald EJ, Skitzki JJ, Okuyama R, Stoolman LM, Chang AE.
    Cancer Res; 2005 Feb 01; 65(3):1063-70. PubMed ID: 15705908
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Expansion of melanoma-specific T cells from lymph nodes of patients in stage III: implications for adoptive immunotherapy in treating cancer.
    Visioni A, Zhang M, Graor H, Kim J.
    Surgery; 2012 Oct 01; 152(4):557-65; discussion 565-6. PubMed ID: 22925133
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. [Clinical significance of CD4+ CD25+ regulatory T-cells detection in tumor-draining lymph nodes of nonsmall cell lung cancer patients].
    Su YJ, Ren K, Li H, Ren XB, Wang CL.
    Zhonghua Zhong Liu Za Zhi; 2007 Dec 01; 29(12):922-6. PubMed ID: 18478932
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.